Faes Farma, S.A.
FAE.MC

$1.23 B
Marketcap
$3.96
Share price
Country
$0.05
Change (1 day)
$4.14
Year High
$3.10
Year Low

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.

marketcap

Faes Farma, S.A. (FAE.MC) - Company Outlook



Company Outlook

Year Receivables Debt Liabilities Assets Current Assets
2023 122.81 M -11,632,515 121.92 M 839.66 M 314.09 M
2022 123.47 M -36,491,322 133.51 M 785.17 M 338.89 M
2021 122.11 M -58,222,085 112.2 M 694.38 M 317.79 M
2020 113.91 M -83,656,513 98.76 M 610.41 M 313.79 M
2019 105.33 M -41,203,405 86.58 M 534.15 M 241.27 M